Thimerosal

Summary

Thimerosal (CHEMBL508338) is a phase-3 clinical-stage small molecule (ATC D08AK06); indicated across 1 condition including hepatitis b virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: D08AK06
• Indications: 1 condition

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL508338
Name	Thimerosal
Type	Small molecule
Max phase	3
ATC	D08AK06

Also known as: Ethylmercury sodium salt, Merthiolate, Mercurothiolate, Merfamin, Mertorgan, Merzonin, NSC-4794, Sodium ethylmercurithiosalicylate, Thimerosal, Thiomersal, Tiomersal, Thiomersalate

Targets

Targets

Broader ChEMBL bioactivity targets: 53 (assay-derived). Sample: Microtubule-associated protein tau, Nuclear receptor ROR-gamma, Survival motor neuron protein, Fructose-bisphosphate aldolase, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor.

Bioactivity

ChEMBL activities: 65 potent at pChembl ≥ 5 of 83 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P0DTD1	8	IC50	10	nM	CHEMBL_ACT_19964292
DRD3	7.54	Ki	29	nM	CHEMBL_ACT_7817071
DRD3	7.19	AC50	65.1	nM	CHEMBL_ACT_25193258
ADRA2B	7.07	Ki	85	nM	CHEMBL_ACT_7817001
DRD3	7.07	IC50	85	nM	CHEMBL_ACT_7817070
LMNA	7	Potency	100	nM	CHEMBL_ACT_3622046
DRD3	6.87	AC50	135.4	nM	CHEMBL_ACT_25194425
ALDH1A1	6.75	Potency	177.8	nM	CHEMBL_ACT_4129373
ADRA2B	6.73	IC50	187	nM	CHEMBL_ACT_7817000
ADRA2A	6.7	Ki	200	nM	CHEMBL_ACT_7816999
HPGD	6.55	Potency	281.8	nM	CHEMBL_ACT_4763625
ADRA2A	6.27	IC50	532	nM	CHEMBL_ACT_7816998
P0DTD1	6.22	IC50	600	nM	CHEMBL_ACT_25516587
P51450	6.2	Potency	631	nM	CHEMBL_ACT_4070479
ADRA2C	6.13	Ki	732	nM	CHEMBL_ACT_7817003
MAPK3	6.11	IC50	774	nM	CHEMBL_ACT_7819186
SLC6A2	6.04	Ki	923	nM	CHEMBL_ACT_7817011
SLC6A2	6.03	IC50	931	nM	CHEMBL_ACT_7817010
Q01827	6.01	AC50	970	nM	CHEMBL_ACT_25197353
HSD17B10	6	Potency	1000	nM	CHEMBL_ACT_3685223
TP53	6	Potency	1000	nM	CHEMBL_ACT_4854517
SLC6A4	5.97	Ki	1070	nM	CHEMBL_ACT_7821218
MAPT	5.95	Potency	1122	nM	CHEMBL_ACT_4012747
P51450	5.95	Potency	1122	nM	CHEMBL_ACT_4801682
ALOX15	5.9	Potency	1259	nM	CHEMBL_ACT_4444773
TP53	5.9	Potency	1259	nM	CHEMBL_ACT_4869737
ADORA3	5.8	AC50	1568	nM	CHEMBL_ACT_25198641
ADORA3	5.72	Ki	1914	nM	CHEMBL_ACT_7816989
SLC6A4	5.7	IC50	2015	nM	CHEMBL_ACT_7821217
HSP90AA1	5.64	AC50	2311	nM	CHEMBL_ACT_7457425

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatitis B virus infection	3	MONDO:0005344	EFO:0004197

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).